News
Garber Announces Advisory Committee for Harvard Law School Dean Search
News
First Harvard Prize Book in Kosovo Established by Harvard Alumni
News
Ryan Murdock ’25 Remembered as Dedicated Advocate and Caring Friend
News
Harvard Faculty Appeal Temporary Suspensions From Widener Library
News
Man Who Managed Clients for High-End Cambridge Brothel Network Pleads Guilty
Dr. Arthur Lee Herbst, associate professor of Obstetrics and Gynecology and leader of the research team which discovered the relation between estrogen and vaginal cancer is leaving Harvard to join the University of Chicago, the University of Chicago announced yesterday.
Herbst will become Joseph Bolivar de Lee Professor of Obstetrics and Gynecology and chairman of that department at Chicago, and will work at Chicago's Lying-In Hospital for Women.
'Outstanding Offer'
"Basically it's an outstanding offer at an outstanding university," Herbst said yesterday. "I'm not mad at anyone here," he added.
In 1971, Herbst and a team of Boston doctors discovered that daughters of women who took diethylstilbestrol (DES), an estrogen compound, during pregnancy to prevent miscarriage had a distinct tendency to develop vaginal cancer.
Herbst and Dr. Robert E. Scully, professor of Pathology at MGH, established a national registry of cancer patients in order to confirm their discovery. Their search found about 250 cases linked to the drug, confirming their hypothesis.
Laments Departure
"Dr. Herbst is an extremely capable man and has made invaluable contributions in the field of estrogen and cancer. We're sorry to see him go," Dr. Kurt J. Isselbacher, Mallinckrodt Professor of Medicine, said last night.
Dr. Kenneth Ryan, Ladd Professor of Obstetrics and Gynecology and chairman of that department, said yesterday, "this university has traditionally been the training place for other schools. His research has been distinguished, and Chicago's gain is our loss."
Herbst said he was offered the position "a while back," but "the details were all worked out in the past month."
Want to keep up with breaking news? Subscribe to our email newsletter.